Aardvark Therapeutics, Inc.
AARDAardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics that activate innate homeostatic pathways to treat metabolic diseases.
Earnings
Next report
Nov 12, 2026 (in a month)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics that activate innate homeostatic pathways to treat metabolic diseases. The company primarily targets Bitter Taste Receptors (TAS2Rs) in the gut to induce the secretion of endogenous signaling molecules like CCK and GLP-1, aiming to alleviate hunger and treat conditions such as Prader-Willi Syndrome and obesity.
Aardvark is a pioneer in targeting TAS2Rs for hunger-associated conditions, currently managing a voluntary clinical pause for its lead candidate while maintaining a proprietary position in gut-restricted small molecules.
FAQ
- What is Aardvark Therapeutics, Inc.'s market cap?
- Aardvark Therapeutics, Inc. (AARD) has a market capitalization of $115.3M and trades on NASDAQ.
- Who are Aardvark Therapeutics, Inc.'s competitors?
- Aardvark Therapeutics, Inc.'s key competitors include Rhythm Pharmaceuticals, Relmada Therapeutics, Bright Minds Biosciences Inc., and others. These companies compete in similar markets and product categories.
- Who does Aardvark Therapeutics, Inc. partner with?
- Aardvark Therapeutics, Inc.'s notable partners include Decheng Capital.
- What subsidiaries does Aardvark Therapeutics, Inc. have?
- Aardvark Therapeutics, Inc.'s subsidiaries include Artisan Therapeutics, Inc., Ardia Therapeutics, Inc..
- Where is Aardvark Therapeutics, Inc. headquartered?
- Aardvark Therapeutics, Inc. is headquartered in United States of America. It has been publicly traded since 2025.